BioCryst stock: BioCryst announces November 4 results date for BioCryst stock
Published on 10/22/2026 at 21:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSReporting date and revenue
- BioCryst Pharmaceuticals announced third-quarter results for November 4, 2026.
- Second-quarter revenue reached USD 218.25 million for the period ended June 30, 2026.
- BioCryst stock costs EUR 6.89 at Lang & Schwarz on October 22, 2026 at 11:45 p.m. CEST.
- Bank of America Securities set a USD 15.00 target on October 9, 2026.
BioCryst Pharmaceuticals announced on October 21, 2026 that it will report third-quarter 2026 financial results on November 4. The company will discuss the figures during an 8:30 a.m. ET conference call, according to BioCryst Pharmaceuticals. At Lang & Schwarz, BioCryst was trading at EUR 6.89 on October 22, 2026 at 11:45 p.m. CEST.
Second-quarter revenue reached USD 218.25 million
For the quarter ended June 30, 2026, revenue rose to USD 218.25 million from USD 163.35 million a year earlier. The same quarter also produced USD 78.40 million in net profit, compared with USD 5.09 million in the prior-year period, according to Markets Insider.
Nasdaq price remains below the yearly high
BioCryst was last quoted at USD 7.75 on Nasdaq on October 22, 2026 at 3:53 p.m. EDT. Its 52-week range was USD 6.23 to USD 11.22, while market capitalization stood at USD 2.0 billion and volume reached 2,276,374 shares. The Nasdaq listing is identified as BCRX in the company's results-date release.
Analyst target leaves a wide gap
Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating and set a USD 15.00 price target on October 9, 2026, as reported by Markets Insider. The target is 93.55 percent above the Nasdaq price of USD 7.75. MarketBeat reported an average target of USD 20.50 from twelve firms on October 10, 2026, alongside seven Buy, four Hold and one Sell ratings, but that consensus is not used as the primary comparison here.
November 4 is the next scheduled date
The next scheduled corporate event is the third-quarter report on November 4, 2026. BioCryst markets ORLADEYO and develops oral and injectable therapies for hereditary angioedema and other rare diseases.
Price and reporting date
The November 4 report will give investors a new period for judging revenue growth and profitability against the second-quarter figures. The stock was trading at EUR 6.89 at Lang & Schwarz on October 22, 2026 at 11:45 p.m. CEST.
The further course of trading is shown by the continuously updated real-time quote of BioCryst Pharmaceuticals stock.
BioCryst Pharmaceuticals market data
- Company: BioCryst Pharmaceuticals, Inc.
- ISIN: US09058V1035
- Ticker: BCRX
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 22, 2026, 11:45 p.m. CEST): EUR 6.89
- Market capitalization: USD 2.0 billion (as of October 22, 2026)
- 52-week range: USD 6.23-USD 11.22 (as of October 22, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 4, 2026
Market context: Market report S&P 500.
